title: Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT).
abstract: BACKGROUND
  It is controversial whether patients with gastric marginal zone lymphomas of mucosa associated lymphoid tissue (MALT) have higher risk of second malignancies. The aim of this study was to define the risk of second malignancies in these patients.
  
  
  METHODS
  We analyzed prospective follow-up data of 146 consecutive patients with gastric MALT lymphoma treated at Aichi Cancer Center Hospital and compared the incidence of second malignancies with that in the general population. We calculated the standardized incidence ratio (SIR), using age- and sex-specific incidence rates from the Aichi Cancer Registry.
  
  
  RESULTS
  The median follow-up period was 74 months. A total of 27 tumors occurred in 22 patients (15.1%), including 19 solid tumors. Of these, nine tumors were detected concomitantly with, and 18 tumors following, the diagnosis of gastric MALT lymphoma. Four patients had two second malignancies each. For the entire group, the SIR of an additional malignancy was 3.39 (95% confidence interval [CI] 2.11-4.66). An increased incidence of solid tumors (SIR 2.91 [1.60-4.22]) and hematologic malignancies (SIR 5.54 [1.70-9.38]) were seen. In addition, there was increased risk for development of second malignancies during follow up (SIR 2.26 [1.21-3.30]). Chemotherapy for treatment of MALT was an independent risk factor for second malignancies (age-sex adjusted hazard ratio 3.98 [1.47-10.79].
  
  
  CONCLUSIONS
  Compared with the general population, patients with gastric MALT lymphoma are at increased risk for second malignancies, including gastric cancer.
authors.affiliation: Department of Endoscopy, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan, mtajika@aichi-cc.jp.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tajika
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Hidemi
authors.initials: H
authors.lastname: Ito
authors.forename: Dai
authors.initials: D
authors.lastname: Chihara
authors.forename: Vikram
authors.initials: V
authors.lastname: Bhatia
authors.forename: Shinya
authors.initials: S
authors.lastname: Kondo
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tanaka
authors.forename: Nobumasa
authors.initials: N
authors.lastname: Mizuno
authors.forename: Kazuo
authors.initials: K
authors.lastname: Hara
authors.forename: Susumu
authors.initials: S
authors.lastname: Hijioka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imaoka
authors.forename: Kazuya
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Tsuneya
authors.initials: T
authors.lastname: Nakamura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yatabe
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamao
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Niwa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000473:pathology; D011446:Prospective Studies; D012042:Registries; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents